Categories
Publications

Does the FDA think these data justify the first full approval of a covid-19 vaccine? – BMJ

I reiterate our call: “slow down and get the science right—there is no legitimate reason to hurry to grant a license to a coronavirus vaccine.”

FDA should be demanding that the companies complete the two year follow-up, as originally planned (even without a placebo group, much can still be learned about safety). They should demand adequate, controlled studies using patient outcomes in the now substantial population of people who have recovered from covid. And regulators should bolster public trust by helping ensure that everyone can access the underlying data.

http://archive.today/2021.08.24-174356/https://blogs.bmj.com/bmj/2021/08/23/does-the-fda-think-these-data-justify-the-first-full-approval-of-a-covid-19-vaccine/

Categories
News

Germany ‘won’t approve’ AstraZeneca vaccine for over-65s – Independent

Germany has recommended the AstraZeneca coronavirus vaccine should only be given to people under the age of 65, according to reports.

The country’s vaccine committee has reportedly said the jab, developed alongside the University of Oxford, should only be offered to people aged between 18 and 64.

It gave a lack of sufficient data on the effectiveness of the inoculation in older people as the reason for the decision in a draft recommendation.

https://www.independent.co.uk/news/world/europe/astrazeneca-covid-vaccine-germany-elderly-b1794128.html